Literature DB >> 12154150

Repetitive transcranial magnetic stimulation treatment of comorbid posttraumatic stress disorder and major depression.

Paul B Rosenberg1, Ritula B Mehndiratta, Yash P Mehndiratta, Angela Wamer, Richard B Rosse, Marshall Balish.   

Abstract

Twelve patients with comorbid posttraumatic stress disorder (PTSD) and major depression underwent repetitive transcranial magnetic stimulation (rTMS) to left frontal cortex as an open-label adjunct to current antidepressant medications. rTMS parameters were as follows: 90% of motor threshold, 1 Hz or 5 Hz, 6,000 stimuli over 10 days. Seventy-five percent of the patients had a clinically significant antidepressant response after rTMS, and 50% had sustained response at 2-month follow-up. Comparable improvements were seen in anxiety, hostility, and insomnia, but only minimal improvement in PTSD symptoms. Left frontal cortical rTMS may have promise for treating depression in PTSD, but there may be a dissociation between treating mood and treating core PTSD symptoms.

Entities:  

Mesh:

Year:  2002        PMID: 12154150     DOI: 10.1176/jnp.14.3.270

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  30 in total

1.  Is there evidence for effectiveness of transcranial magnetic stimulation in the treatment of psychiatric disorders?

Authors:  Biju Basil; Jamal Mahmud; Maju Mathews; Carlos Rodriguez; Babatunde Adetunji
Journal:  Psychiatry (Edgmont)       Date:  2005-11

2.  Neuromodulation and Transcranial Mag Netic Stimulation (TMS): A 21st Century Paradigm for Therapeutics in Psychiatry.

Authors:  John P O'Reardon; Andrew D Peshek; Rocio Romero; Pilar Cristancho
Journal:  Psychiatry (Edgmont)       Date:  2006-01

3.  Increased positive emotional memory after repetitive transcranial magnetic stimulation over the orbitofrontal cortex.

Authors:  Dennis J L G Schutter; Jack van Honk
Journal:  J Psychiatry Neurosci       Date:  2006-03       Impact factor: 6.186

4.  Repetitive TMS combined with exposure therapy for PTSD: a preliminary study.

Authors:  Elizabeth A Osuch; Brenda E Benson; David A Luckenbaugh; Marilla Geraci; Robert M Post; Una McCann
Journal:  J Anxiety Disord       Date:  2008-03-28

5.  Repetitive transcranial magnetic stimulation over the dorsolateral prefrontal cortex for treating posttraumatic stress disorder: an exploratory meta-analysis of randomized, double-blind and sham-controlled trials.

Authors:  Marcelo T Berlim; Frederique Van Den Eynde
Journal:  Can J Psychiatry       Date:  2014-09       Impact factor: 4.356

Review 6.  Transcranial Magnetic Stimulation : A New Therapeutic Tool in Psychiatry.

Authors:  A A Pawar; D Saldanha; S Chaudhury; Vssr Ryali; K Srivastava
Journal:  Med J Armed Forces India       Date:  2011-07-21

7.  Treating Post-traumatic Stress Disorder with Neuromodulation Therapies: Transcranial Magnetic Stimulation, Transcranial Direct Current Stimulation, and Deep Brain Stimulation.

Authors:  Flavia Venetucci Gouveia; Benjamin Davidson; Ying Meng; Darryl Christopher Gidyk; Jennifer S Rabin; Enoch Ng; Agessandro Abrahao; Nir Lipsman; Peter Giacobbe; Clement Hamani
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

8.  Low-frequency repetitive transcranial magnetic stimulation (rTMS) affects event-related potential measures of novelty processing in autism.

Authors:  Estate Sokhadze; Joshua Baruth; Allan Tasman; Mehreen Mansoor; Rajesh Ramaswamy; Lonnie Sears; Grace Mathai; Ayman El-Baz; Manuel F Casanova
Journal:  Appl Psychophysiol Biofeedback       Date:  2010-06

9.  Nonpharmacologic treatment of insomnia.

Authors:  Melanie K Means; Margaret D Lineberger; Jack D Edinger
Journal:  Curr Treat Options Neurol       Date:  2008-09       Impact factor: 3.598

Review 10.  A Review of Transcranial Magnetic Stimulation as a Treatment for Post-Traumatic Stress Disorder.

Authors:  Caroline Clark; Jeffrey Cole; Christine Winter; Kathy Williams; Geoffrey Grammer
Journal:  Curr Psychiatry Rep       Date:  2015-10       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.